期刊文献+

乳腺癌组织中COX-2、VECF—C表达与淋巴转移的相关性研究 被引量:1

Relationship between expressions of COX-2, VEGF-C in breast cancer and lymphatic metastasis
原文传递
导出
摘要 目的探讨COX-2、VEGF-C在人乳腺癌组织中的表达及其与淋巴转移之间的关系。方法运用免疫组织化学SABC法检测COX-2和VEGF—C在乳腺癌组织中的表达情况。结果60例乳腺癌组织中COX-2和VEGF-C的表达阳性率分别为66.7%和60.0%,且二者表达呈正相关(r=0.429,P〈0.05)。COX-2阳性、VEGF-C阳性组淋巴转移的发生率(80.0%)明显高于COX-2阴性、VEGF-C阴性组(21.4%;P〈0.05)。结论COX-2、VEGF-C在乳腺癌组织中呈过表达,呈正相关关系,且与乳腺癌的淋巴转移关系密切,COX-2表达上调可能促使VEGF-C的过表达,诱导肿瘤淋巴管的生成,从而导致乳腺癌细胞淋巴转移的发生。 Objective To detect the expressions of COX-2 and VEGF-C in breast cancer and to explore the relationship between their expressions and lymphatic metastasis. Methods Immunohistochemical staining (SABC) was used to detect the expressions of COX-2 and VEGF-C proteins in 60 cases of breast cancer. Results The positive rate of COX-2 and VEGF-C in breast cancer were 66. 7% and 60. 0%, and the expression of COX-2 was positively correlated with VEGF-C ( r = 0. 429, P 〈 0.05). COX-2 and VEGF-C expressions were positively correlated with lymphatic metastasis ( P 〈 0. 05 ). The lymphatic metastasis rate in the positive group of COX-2 and VEGF-C were higher than that in the negative group of COX-2 and VEGF-C. Conclusion Over expression of COX-2 and VEGF-C were observed in breast cancer, and closely related to lymphatic metastasis. COX-2 has positive correlation with VEGF-C and was correlated with lymphatic metastasis of breast cancer. COX-2 may promote the over expression of VEGF-C in tumor cells and cause lymphatic metastasis.
出处 《国际外科学杂志》 2008年第8期521-524,共4页 International Journal of Surgery
关键词 乳腺癌 淋巴转移 环氧化酶-2(COX-2) 血管内皮生长因子C(VEGF-C) breast cancer lymphatic metastasis cyclooxyenase-2 (COX-2) vascular endothelial growth factor-C (VEGF-C)
  • 相关文献

参考文献8

  • 1Su JL, Shih JY, Yen ML, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C upregulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma[ J ]. Cancer Res, 2004, 64 (2) :554-564.
  • 2Kawasaki H, Altieri DC, Lu CD , et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer [ J ]. Cancer Res, 1998, 58 (22) :5071-5074.
  • 3战淑珺,江泽飞,宋三泰.COX-2抑制剂与乳腺癌关系研究进展[J].癌症进展,2005,3(1):45-48. 被引量:5
  • 4Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer [ J ]. Cancer Res, 2002, 62(3) :632-635.
  • 5Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 ( VEGFR-3 ) and KDR ( VEGFR-2 ) receptor tyrosine kinases [ J ]. EMBO J, 1996, 15(2) :290-298.
  • 6Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis [J]. Physiol Rev, 2002, 82(3):673-700.
  • 7Makinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3 [ J ]. EMBO J, 2001, 20 ( 17 ) : 4762-4773.
  • 8Mattila MM, Ruohola JK, Karpanen T, et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors[J], Int J Cancer, 2002, 98(6) :946-951.

二级参考文献14

  • 1[5]Davies GLS. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol, 2003, 86 (3 ~ 5) :495
  • 2[6]Pesenti E, Masferrer JL, Salle E, et al. Effect of exemestane and celecoxib alone or in combination on DMBA - induced mammary carcinoma in rats. Breast Cancer Res Treat, 2001, 69 (3):288
  • 3[7]Arun B, Zhang H, Mirza NQ, et al. Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Res Treat,2001, 69 (3) :234
  • 4[8]Paul EG, et al. Breast cancer prevention: Clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol,2003, 86 (3~5) :487
  • 5[9]Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report. J Steroid Biochem Mol Biol, 2003, 86 (3 ~ 5) :443
  • 6[10]Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA - dependent and independent effects. Br J Cancer, 2003, 88 (10) :1631
  • 7[11]Lois M, Witters LM, Crispino J, et al. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol,2003, 26 (4) : S92
  • 8[12]Simeone AM, Li YJ, Broemeling LD, et al. Cyclooxygenase - 2 is essential for HER - 2/neu to suppress N- (4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells.Cancer Res, 2004, 64 (4) :1224
  • 9[13]Michael MS, Badr MZ, Badawi AF. Inhibition of cyclooxygenase - 2 and activation of peroxisome proliferator - activated receptor- gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med, 2003, 11(6) :733
  • 10[14]Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.Clin Cancer Res, 2003, 9 (4) :1566

共引文献4

同被引文献14

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部